Nat Commun:亚洲乳腺癌的分子表征揭示疾病的人群特异性

2020-12-25 xiaozeng MedSci原创

乳腺癌是一种异质性疾病,一般根据组织病理学和临床人口统计学特征对该疾病进行治疗选择的指导。如在ER+(雌激素受体阳性)肿瘤中采用内分泌治疗,在Her2+肿瘤中采用HER2靶向治疗以及通过化疗的方式治疗

乳腺癌是一种异质性疾病,一般根据组织病理学和临床人口统计学特征对该疾病进行治疗选择的指导。如在ER+(雌激素受体阳性)肿瘤中采用内分泌治疗,在Her2+肿瘤中采用HER2靶向治疗以及通过化疗的方式治疗预后较差的患者。

乳腺肿瘤的分子表征的研究有利于开发新的疗法以及合适的治疗选择。既往的研究结果(主要在欧洲血统的女性中进行)遗传、生活方式和环境因素均存在差异的其他人群的应用有一定的借鉴。然而,非白人乳腺癌患者的相关研究仍缺乏详细信息。

马来西亚乳腺癌患者的分子亚型分析

在该研究中,研究人员分析了560例马来西亚乳腺肿瘤患者的基因突变、转录和拷贝数情况,并对亚洲和白人女性患乳腺癌的情况进行了比较分析。研究人员发现,相比于白人乳腺癌患者,在ER+亚洲乳腺癌患者中,具有HER2分子亚型的患病率升高,携带TP53体细胞突变的患者患病率更高。

马来西亚乳腺癌患者的肿瘤免疫微环境分析

进一步研究显示,亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。HER2亚型以及较高的免疫评分则与患者的存活率提高相关,而携带TP53体细胞突变以及ER+状态对应着较差的患者生存率。


总而言之,该研究结果揭示,在不同人群中的差异对于乳腺癌的理解提供了见解,并为不同人群中的精准医疗奠定了一定的基础。


原始出处:

Pan, JW., Zabidi, M.M.A., Ng, PS. et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun 11, 6433 (22 December 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2021-12-03 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2021-08-12 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2020-12-27 oo902

    亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2020-12-26 ms5000000518166734

    已读,受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1899445, encodeId=610a189944519, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 22 23:49:21 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087861, encodeId=f03f208e861ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 03 20:49:21 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884864, encodeId=bb991884864ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 12 18:49:21 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911415, encodeId=d263911415f2, content=亚洲乳腺癌患者的免疫评分升高,说明其对于免疫检查点抑制剂具有潜在的临床反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:14:55 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911071, encodeId=8b7e9110e135, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Sat Dec 26 12:27:15 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910763, encodeId=a57e910e63e6, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Fri Dec 25 04:23:30 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2020-12-25 ms6000001700483633

    已学习

    0

相关资讯

NAT COMMUN:多基因风险如何影响整个生命过程中患乳腺癌的概率?

研究人员表明,在乳腺癌诊断后,PRS升高的个体患对侧乳腺癌的风险升高,而且PRS可以大大改善其女性一级亲属的风险评估。

EOC202海外试验显著改善晚期乳腺癌患者总生存期,亿腾景昂药业在中国启动该产品II期临床

近日,亿腾景昂药业在研产品EOC202(eftilagimod alpha)的海外合作伙伴Immutep正式对外公布了其在欧洲开展的临床IIb期试验(AIPAC)结果

Cancer Res :超25万人研究数据显示,口服避孕药可预防卵巢癌和子宫内膜癌

卵巢癌和子宫内膜癌是最常见的三种妇科癌症,对女性健康有着非常大的危害。与卵巢癌相比,子宫内膜癌更为常见,由于其早期易发现,症状更明显,因此死亡率较低。然而,卵巢癌对女性来说是最致命的癌症之一,通常只有

突破!乳腺癌疫苗GP2研究发现对HER2阳性乳腺癌术后,5年无一复发!

HER2+乳腺癌的标准治疗方案是曲妥珠单抗和帕妥珠单抗。当然,全球治疗HER2+乳腺癌的药物至少获批了9款,除曲妥珠单抗和帕妥珠单抗外,拉帕替尼,T-DM1,奈拉替尼,吡咯替尼,DS-8201,图卡替

Br J Cancer:RON促进ESR1突变型乳腺癌的治疗耐药性

全球每年有超过60万妇女死于转移性乳腺癌(MBC)。尽管有效的内分泌治疗和靶向疗法可以用于雌激素受体(ER)阳性乳腺癌(BC)的治疗,但仍有20%的妇女出现癌症的复发和/或转移。

J Clin Oncol:他莫昔芬联合卵巢抑制功能可显著延长绝经前乳腺癌患者的无病生存期

完成化疗后的绝经前乳腺癌患者中,在他莫昔芬(TAM)治疗的基础上加用卵巢功能抑制(OFS)5年,可延长患者的无病生存期(DFS)。本研究评价了在TAM基础上增加2年OFS对激素受体阳性乳腺癌患者化疗后